Moreover, p38 kinase inhibitor (pirfenidone) has been approved for the treatment of PF [53], and subsequent studies have further confirmed the association between TGF-β and p38MAPK in PF [54, 55]. This evidence concerns the gene TGFB1 and pemphigus foliaceus.